Guidelines from the American Society of Hematology (ASH) review panel recommend standards of care for individualized acute myeloid leukemia (AML) treatments. For patients with newly diagnosed AML, ASH recommends intensive antileukemic therapy. Patients who cannot tolerate intensive therapy should be treated with a hypomethylating agent or low-dose cytarabine. ASH also recommends post-remission therapy for patients in remission who are ineligible for stem cell transplantation. For patients no longer receiving antileukemic therapy, ASH supports red blood cell transfusion, even if the patient is under hospice care.
Click here to learn more.